Cytori Therapeutics Inc (NASDAQ:CYTX) announced today preliminary 12 month follow-up data from the 12 patient investigator initiated Scleradec-I clinical trial conducted by Prof. B. Granel and Prof. G. Magalon from the Assistance Publique des Hôpitaux de Marseille.

In the previously published six month follow-up data, Cytori’s ECCS-50 therapeutic showed:

  • Improvement in Cochin Hand Function Scale (CHFS) from mean of 48.5 at baseline to 21.2 at six months
  • Improvement in Hand Pain (Visual Analog Scale) from mean of 59.4 at baseline to 17.8 at six months
  • Improvement in Raynaud’s Condition Score (RCS) from mean of 7.2 at baseline to 2.9 at six months
  • Improvement in Scleroderma Health Assessment Questionnaire (SHAQ) score from mean of 1.4 at baseline to 0.8 at six months

The manuscript describing these data in detail can be viewed at

A preliminary assessment for 12 month follow-up data has been reviewed by the Company which management believes reflects:

  • No reports of adverse events or safety concerns
  • Average values for CHFS, RCS, and SHAQ score are statistically consistent with those at the 6 month follow up visit
  • While the average hand pain at 12 months was lower than that at baseline (reflecting overall symptom improvement over baseline), there was an approximately 50% reduction in the average therapeutic benefit on hand pain from six to twelve months

The investigators have prepared and submitted for publication a scientific manuscript based on final 12 month data. Once this manuscript has been accepted for publication and a publication date announced, Cytori will provide an update to investors. (Original Source)

Shares of Cytori closed last Friday at $1.24 . CYTX has a 1-year high of $2.63 and a 1-year low of $0.36. The stock’s 50-day moving average is $1.17 and it’s 200-day moving average is $0.66.

On the ratings front, Cytori has been the subject of a number of recent research reports. In a report issued on April 7, Maxim Group analyst Jason Kolbert reiterated a Buy rating on CYTX, with a price target of $7, which implies an upside of 464.5% from current levels. Separately, on April 6, Laidlaw’s Yale Jen reiterated a Buy rating on the stock and has a price target of $4.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Yale Jen have a total average return of 11.7% and 48.0% respectively. Kolbert has a success rate of 48.8% and is ranked #233 out of 3574 analysts, while Jen has a success rate of 66.7% and is ranked #522.

Cytori Therapeutics Inc is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns.